Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026

A retrospective study by researchers in Turkey looked at a simple index based on three routine blood measurements: platelets, albumin and bilirubin. The “PALBI” index reflects how pulmonary hypertension affects both the heart and the liver. Researchers applied it to 3,432 people, including 1,520 patients with pulmonary hypertension identified by echocardiography. The final cohort comprised […]

Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026

In pulmonary arterial hypertension there are significant disparities in epidemiology, clinical outcomes, and healthcare access that disproportionately affect historically neglected populations, including Black Americans, Hispanic Americans, and American Indians. A State-of-the-Art review recently published on CHEST examines the disparities in the three groups. Key points: Conclusion: These disparities stem from structural/socioeconomic barriers and discrimination—not biological differences.

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026 Read Post »

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026

A recent article by Dr. Iain Armstrong and Peter Winter examines a critical blind spot in digital health ethics known as “misrecognition”, which occurs when artificial intelligence systems evaluate patients solely through easily quantifiable metrics. By prioritizing standardized data over the complex, subjective realities of living with a chronic illness, AI tools inadvertently foster epistemic

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026

Despite the comprehensive, evidence-based guidance offered by current international guidelines on the management of pulmonary hypertension, clinicians frequently encounter situations where the correct diagnosis or the most appropriate treatment remains uncertain. Methods A panel of pulmonary hypertension experts identified ten real-world diagnostic and management dilemmas during 2024–2025. For each, the available evidence was reviewed and

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026 Read Post »

Pulmonary Hypertension Global Patient Survey (PHGPS), key insights and campaign pack

In October 2023, the Pulmonary Vascular Research Institute launched the Pulmonary Hypertension Global Patient Survey (PHGPS) to better understand the reality of what it is like to live with the condition worldwide. Almost 4,000 patients and carers from 90 countries took part in the survey and shared their experiences, which makes the PHGPS one of

Pulmonary Hypertension Global Patient Survey (PHGPS), key insights and campaign pack Read Post »

Pulmonary hypertension, Nature Reviews Disease Primers, January 4, 2024 

This comprehensive Nature Reviews Disease Primers paper provides an authoritative overview of pulmonary hypertension (PH) globally, with particular attention to disparities between high-income (HICs) and low- and middle-income countries (LMICs). Key Points Classification and Prevalence: pulmonary hypertension is defined as mean pulmonary artery pressure >20 mmHg and comprises five groups: Group 1 (pulmonary arterial hypertension/PAH

Pulmonary hypertension, Nature Reviews Disease Primers, January 4, 2024  Read Post »

From Ancient Mysteries to Modern Miracles: The Incredible Journey of Pulmonary Circulation, Adam Torbicki, “Diagnostics”

INTRODUCTION Ever wondered how we went from completely misunderstanding blood flow for 1,400 years to performing open-heart surgery? A fascinating historical review by Prof. Adam Torbicki, published in Diagnostics (2021), reminds us that while most modern clinicians “look forward, expecting new pathophysiological pathways to be explored,” few take time “to look into the past.” Yet

From Ancient Mysteries to Modern Miracles: The Incredible Journey of Pulmonary Circulation, Adam Torbicki, “Diagnostics” Read Post »

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025

Pulmonary hypertension (PH) is hard to diagnose, especially in places with limited medical resources, but catching it early is crucial for treatment. A group of researchers from China conducted a retrospective cohort study with 4,576 patients, including 2,288 pulmonary hypertension cases, who underwent chest X-rays (CXR) followed by right heart catheterization (RHC) or transthoracic echocardiography

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025 Read Post »

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024

The full proceedings of the World Symposium on Pulmonary Hypertension which was held in Barcelona 29.6-1.7, 2024, have now been published in the European Respiratory Journal at this link. The proceedings cover the work of the 15 task forces; Task Force n°1’s article is titled “Exploring the patient perspective in pulmonary hypertension” (see below for

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024 Read Post »

TRANSLATE »
Scroll to Top